<DOC>
	<DOCNO>NCT02409771</DOCNO>
	<brief_summary>The purpose clinical trial evaluate effectiveness PRECIZON Presbyopic .</brief_summary>
	<brief_title>Clinical Trial With PRECIZON Presbyopic</brief_title>
	<detailed_description>Prospective , open-label , single-arm , multicenter clinical evaluation 3 month follow-up . The PRECIZON Presbyopic lens intend implantation capsular bag , indicate optical correction aphakia adult crystalline lens remove desire presbyopia correction . The main objective evaluate ability PRECIZON Presbyopic provide near , intermediate distance vision patient undergoing cataract extraction / Clear Lens Exchange ( CLE ) intraocular lens implantation . Study result use CE-approval registration marketing purpose .</detailed_description>
	<mesh_term>Cataract</mesh_term>
	<mesh_term>Presbyopia</mesh_term>
	<criteria>Presbyopic Cataract patient Clear Lens Extraction ( CLE ) candidate Patients wish spectacle independent near far vision Patient lifestyle outlook fit multifocal IOL implantation Qualifies bilateral implantation Patient must calculate IOL power within available diopter range Expected best correct visual acuity 0.5 Snellen decimal good IOL implantation . No secondary surgical procedure plan course study Availability , willingness sufficient cognitive awareness physical ability comply examination procedure throughout entire duration study Patients must provide write informed consent The predict keratometric postoperative astigmatism ( calculated respect surgical induce astigmatism ) must &lt; 1.0 D. Ocular disease cataract may predispose future complication might confound outcome investigation ( e.g . anterior segment pathology , glaucoma , corneal dystrophy , ocular inflammation , pseudoexfoliation syndrome , retinal disorder ) Acute chronic disease illness use medication could confound outcome study increase risk subject Endothelial cell count &lt; 1500 cells/mm2 Amblyopia Congenital eye abnormality Previous ocular surgery might confound outcome investigation increase risk patient Concurrent participation participation last 30 day clinical trial Patient must pregnant another condition associate fluctuation hormone could lead refractive change</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>